WO2007048046A3 - Sirna silencing of filovirus gene expression - Google Patents

Sirna silencing of filovirus gene expression Download PDF

Info

Publication number
WO2007048046A3
WO2007048046A3 PCT/US2006/041336 US2006041336W WO2007048046A3 WO 2007048046 A3 WO2007048046 A3 WO 2007048046A3 US 2006041336 W US2006041336 W US 2006041336W WO 2007048046 A3 WO2007048046 A3 WO 2007048046A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
filovirus gene
filovirus
sirna silencing
sirna
Prior art date
Application number
PCT/US2006/041336
Other languages
French (fr)
Other versions
WO2007048046A2 (en
WO2007048046A9 (en
Inventor
Ian Maclachlan
Vandana Sood
Thomas W Geisbert
Lisa E Hensley
Elliott Kagan
Original Assignee
Protiva Biotherapeutics Inc
Ian Maclachlan
Vandana Sood
Thomas W Geisbert
Lisa E Hensley
Elliott Kagan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protiva Biotherapeutics Inc, Ian Maclachlan, Vandana Sood, Thomas W Geisbert, Lisa E Hensley, Elliott Kagan filed Critical Protiva Biotherapeutics Inc
Publication of WO2007048046A2 publication Critical patent/WO2007048046A2/en
Publication of WO2007048046A9 publication Critical patent/WO2007048046A9/en
Publication of WO2007048046A3 publication Critical patent/WO2007048046A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.
PCT/US2006/041336 2005-10-20 2006-10-20 Sirna silencing of filovirus gene expression WO2007048046A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72947605P 2005-10-20 2005-10-20
US60/729,476 2005-10-20

Publications (3)

Publication Number Publication Date
WO2007048046A2 WO2007048046A2 (en) 2007-04-26
WO2007048046A9 WO2007048046A9 (en) 2007-06-14
WO2007048046A3 true WO2007048046A3 (en) 2007-10-18

Family

ID=37872493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041336 WO2007048046A2 (en) 2005-10-20 2006-10-20 Sirna silencing of filovirus gene expression

Country Status (2)

Country Link
US (2) US7838658B2 (en)
WO (1) WO2007048046A2 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969543B2 (en) * 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
JP2008504827A (en) * 2004-07-02 2008-02-21 プロチバ バイオセラピューティクス インコーポレイティッド Immunostimulatory siRNA molecules and methods of use thereof
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
EP1948674A4 (en) * 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modified sirna molecules and uses thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2008033285A2 (en) * 2006-09-15 2008-03-20 The Trustees Of Culumbia University In The City Of New York Delivery of double-stranded rna into the central nervous system
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
US8067390B2 (en) * 2007-03-02 2011-11-29 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using siRNA in neutral liposomes
AP3018A (en) 2007-03-29 2014-10-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expressionof a gene from the ebola
US20090054334A1 (en) * 2007-05-23 2009-02-26 Mutz Mitchell W Combinatorial improvement of bifunctional drug properties
WO2008156853A2 (en) * 2007-06-20 2008-12-24 The Board Of Regents Of The University Of Texas System Inhibition of filovirus entry into cells and uses thereof
US20090142391A1 (en) * 2007-08-14 2009-06-04 Mutz Mitchell W Conjugated RNAi Therapeutics
US20100284993A1 (en) * 2007-10-24 2010-11-11 Mutz Mitchell W Enhancing the Efficacy of Anti-Infective Therapeutics
WO2009082817A1 (en) * 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
EP2396409A2 (en) * 2009-02-10 2011-12-21 Idera Pharmaceuticals, Inc. Synthetic rna-based agonists of tlr7
EP2449106B1 (en) * 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
WO2011020023A2 (en) * 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
DK2558578T3 (en) 2010-04-13 2016-01-25 Life Technologies Corp CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function
JP2013527856A (en) 2010-05-12 2013-07-04 プロチバ バイオセラピューティクス インコーポレイティッド Cationic lipids and methods of use
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
JP6073795B2 (en) * 2010-10-27 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1)
EP2812434B1 (en) * 2012-02-09 2018-03-28 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
ES2883590T3 (en) 2012-12-12 2021-12-09 Broad Inst Inc Supply, modification and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CA2906663A1 (en) 2013-03-15 2014-09-18 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
RU2716420C2 (en) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Delivery and use of systems of crispr-cas, vectors and compositions for targeted action and therapy in liver
CN105793425B (en) 2013-06-17 2021-10-26 布罗德研究所有限公司 Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components
RU2725502C2 (en) 2013-06-17 2020-07-02 Те Брод Инститьют Инк. Delivery, construction and optimization of systems, methods and compositions for targeted action and modeling of diseases and disorders of postmitotic cells
AU2014361781B2 (en) 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
JP6712948B2 (en) 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド Compositions and methods of using the CRISPR-cas system in nucleotide repeat disorders
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
MX2016007327A (en) 2013-12-12 2017-03-06 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components.
BR112016013207A2 (en) 2013-12-12 2017-09-26 Massachusetts Inst Technology administration, use and therapeutic applications of crisp systems and compositions for hbv and viral disorders and diseases
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
CN106536056B (en) 2014-06-13 2021-07-16 儿童医学中心公司 Products and methods for isolating mitochondria
JP6240570B2 (en) * 2014-07-17 2017-11-29 富士フイルム株式会社 Lipid particles and nucleic acid delivery carriers
WO2016028682A1 (en) 2014-08-17 2016-02-25 The Broad Institute Inc. Genome editing using cas9 nickases
US9765333B2 (en) 2014-08-21 2017-09-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing marburg virus gene expression
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
CN105063044A (en) * 2014-10-17 2015-11-18 苏州圣诺生物医药技术有限公司 Active molecule capable of suppressing gene replication of Ebola virus and usage method thereof
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
EP3233880A1 (en) 2014-12-16 2017-10-25 Novartis AG End capped nucleic acid molecules
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
EP3098326A1 (en) * 2015-05-27 2016-11-30 Institut Pasteur Isothermal amplification assay for rapid and accurate detection of hemorrhagic fever viruses in clinical samples
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205745A2 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
FI3430134T3 (en) 2015-06-18 2023-01-13 Novel crispr enzymes and systems
CN108290933A (en) 2015-06-18 2018-07-17 布罗德研究所有限公司 Reduce the CRISPR enzyme mutants of undershooting-effect
WO2017031370A1 (en) 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CA3024543A1 (en) 2015-10-22 2017-04-27 The Broad Institute, Inc. Type vi-b crispr enzymes and systems
EP3368687B1 (en) 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions and methods for targeting cancer-specific sequence variations
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3383411A4 (en) 2015-11-30 2019-07-03 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
US20190233814A1 (en) 2015-12-18 2019-08-01 The Broad Institute, Inc. Novel crispr enzymes and systems
CA3006015A1 (en) * 2015-12-31 2017-07-06 Ionis Pharmaceuticals, Inc. Methods for reducing ataxin-2 expression
KR102424476B1 (en) 2016-04-19 2022-07-25 더 브로드 인스티튜트, 인코퍼레이티드 Novel CRISPR Enzymes and Systems
AU2017253107B2 (en) 2016-04-19 2023-07-20 Massachusetts Institute Of Technology CPF1 complexes with reduced indel activity
CA3026110A1 (en) 2016-04-19 2017-11-02 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3455357A1 (en) 2016-06-17 2019-03-20 The Broad Institute Inc. Type vi crispr orthologs and systems
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
KR102185464B1 (en) 2017-03-15 2020-12-03 매사추세츠 인스티튜트 오브 테크놀로지 New CAS13B Ortholog CRISPR Enzyme and System
WO2018191388A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
US20200405639A1 (en) 2017-04-14 2020-12-31 The Broad Institute, Inc. Novel delivery of large payloads
WO2018204777A2 (en) 2017-05-05 2018-11-08 The Broad Institute, Inc. Methods for identification and modification of lncrna associated with target genotypes and phenotypes
JP7395355B2 (en) 2017-05-08 2023-12-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Compositions and uses thereof for promoting membrane fusion
US20200123203A1 (en) 2017-06-13 2020-04-23 Flagship Pioneering Innovations V, Inc. Compositions comprising curons and uses thereof
AU2018338318B2 (en) 2017-09-21 2022-12-22 Massachusetts Institute Of Technology Systems, methods, and compositions for targeted nucleic acid editing
US20200255828A1 (en) 2017-10-04 2020-08-13 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
JP2021532815A (en) 2018-08-07 2021-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド New Cas12b enzyme and system
US20210317429A1 (en) 2018-08-20 2021-10-14 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
BR112021006539A2 (en) 2018-10-09 2021-07-06 Univ British Columbia compositions and competent systems of vesicles competent for transfection free of organic solvents and detergents and related methods
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
CN111378656B (en) * 2018-12-28 2022-07-26 苏州瑞博生物技术股份有限公司 Nucleic acid for inhibiting Ebola virus, pharmaceutical composition containing nucleic acid and application of pharmaceutical composition
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
US20220220469A1 (en) 2019-05-20 2022-07-14 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
JP2023553343A (en) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド Lipid nanoparticles and related methods of use for delivering nucleic acids
WO2022261394A1 (en) 2021-06-11 2022-12-15 LifeEDIT Therapeutics, Inc. Rna polymerase iii promoters and methods of use
WO2023144798A1 (en) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2024033901A1 (en) 2022-08-12 2024-02-15 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4335310B2 (en) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Lipid-nucleic acid particles prepared through hydrophobic lipid-nucleic acid complex intermediates and use for gene transfer
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6680068B2 (en) * 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
TR200401292T3 (en) * 2000-12-01 2004-07-21 Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften the rnaágirişimineáyoláaçanáküçükárnaámolekül
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20040142892A1 (en) 2001-04-30 2004-07-22 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
EP3100719A3 (en) 2002-05-15 2017-02-22 California Pacific Medical Center Delivery of nucleic acid-like compounds
AU2004205895B2 (en) 2003-01-16 2009-02-26 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of ICAM-1
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
MXPA05013746A (en) 2003-06-18 2006-06-27 Yissum Res Dev Co Sphingoid polyalkylamine conjugates for vaccination.
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
NZ592917A (en) 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
ATE536418T1 (en) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc LIPID ENCAPSULATED INTERFERENCE RNA
EP1781593B1 (en) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Cationic lipids and methods of use
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2006074546A1 (en) 2005-01-13 2006-07-20 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modified sirna molecules and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ENTERLEIN SVEN ET AL: "VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY MAR 2006, vol. 50, no. 3, March 2006 (2006-03-01), pages 984 - 993, XP002430762, ISSN: 0066-4804 *
FELDMANN HEINZ ET AL: "Therapy and prophylaxis of Ebola virus infections.", CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000) AUG 2005, vol. 6, no. 8, August 2005 (2005-08-01), pages 823 - 830, XP008078171, ISSN: 1472-4472 *
FOWLER TRENT ET AL: "Inhibition of Marburg virus protein expression and viral release by RNA interference.", THE JOURNAL OF GENERAL VIROLOGY APR 2005, vol. 86, no. Pt 4, April 2005 (2005-04-01), pages 1181 - 1188, XP002430761, ISSN: 0022-1317 *
GEISBERT THOMAS W ET AL: "Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.", THE JOURNAL OF INFECTIOUS DISEASES 15 JUN 2006, vol. 193, no. 12, 15 June 2006 (2006-06-15), pages 1650 - 1657, XP008078155, ISSN: 0022-1899 *
WARFIELD KELLY L ET AL: "Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.", PLOS PATHOGENS JAN 2006, vol. 2, no. 1, January 2006 (2006-01-01), pages e1, XP002430763, ISSN: 1553-7366 *

Also Published As

Publication number Publication date
WO2007048046A2 (en) 2007-04-26
US20110177131A1 (en) 2011-07-21
WO2007048046A9 (en) 2007-06-14
US7838658B2 (en) 2010-11-23
US20070135370A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2007048046A3 (en) Sirna silencing of filovirus gene expression
EP1828219A4 (en) Sirna silencing of apolipoprotein b
EP1948674A4 (en) Modified sirna molecules and uses thereof
WO2005007196A3 (en) Lipid encapsulated interfering rna
WO2009129319A3 (en) Silencing of csn5 gene expression using interfering rna
WO2006036916A3 (en) Rnai modulation of apob and uses thereof
WO2006031267A3 (en) Rna interference suppression of neurodegenerative diseases and methods of use thereof
WO2005062937A3 (en) Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
WO2006015389A3 (en) Methods and compositions for enhancing the efficacy and specificity of rna silencing
HK1103391A1 (en) Cationic lipids and methods of use
WO2005047505A3 (en) Methods and products for expression of micro rnas
EP1951737A4 (en) Rnai inhibition of influenza virus replication
WO2007075626A3 (en) Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments
WO2006066158A3 (en) Rnai modulation of mll-af4 and uses thereof
WO2004045543A3 (en) Functional and hyperfunctional sirna
WO2004058940A3 (en) Sirna-mediated gene silencing
WO2006127899A3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
WO2007021896A3 (en) Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
WO2005001043A3 (en) METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi
WO2005042708A3 (en) METHOD OF DESIGNING siRNAS FOR GENE SILENCING
WO2009039198A3 (en) Generation of hyperstable mrnas
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
WO2007014075A3 (en) Rnai modulation of the rho-a gene in research models
WO2007143086A3 (en) Delivery method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06826496

Country of ref document: EP

Kind code of ref document: A2